Clinical Trial Update: Efficacy of Azithromycin to Prevent Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating whether azithromycin prevents bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiolitis Obliterans Syndrome
• Malignant Hematological Diseases

Drugs mentioned

• Azithromycin (azithromycin)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Malignant Hematological Diseases | Phase 3 | Status: UNKNOWN